Erythrocytosis on AndroGel (testosterone topical): Incidence, Severity, and Realistic Expectations

At a glance

• Incidence (hematocrit >54%): ~3 to 6% in controlled AndroGel trials; lower than injectable formulations (~18% in comparable study arms)
• Typical onset: 3 to 6 months after starting or after a dose increase; occasionally earlier in high-risk patients
• Severity distribution: Majority mild-to-moderate (hematocrit 52 to 56%); severe polycythemia vera-range elevations rare on gel formulations
• First-line management: Dose reduction, increased hydration, therapeutic phlebotomy if hematocrit >54% with symptoms or >56% regardless of symptoms
• Escalation threshold: Hematocrit >54% on repeat measurement, or any elevation with symptoms (headache, flushing, visual changes, dyspnea)
• Discontinuation considered when: Persistent hematocrit >56% despite dose reduction and phlebotomy, or thromboembolic event
• Monitoring schedule: Baseline, then at 3 and 6 months, then annually if stable

What Erythrocytosis Actually Means in This Context

Erythrocytosis is an increase in red blood cell mass, measured clinically as a rise in hematocrit or hemoglobin. Testosterone stimulates erythropoiesis primarily by increasing erythropoietin (EPO) secretion from the kidneys and by directly stimulating erythroid progenitor cells in bone marrow. The result is a denser, more viscous blood that, at high enough levels, raises thrombotic risk.

The FDA-approved prescribing information for AndroGel 1.62% lists polycythemia as a known adverse reaction and instructs prescribers to check hematocrit before initiating therapy, at 3 to 6 months, and annually thereafter. This is not a rare or theoretical warning; it reflects consistent signal across the testosterone drug class.

The key distinction with transdermal gel is pharmacokinetic. Gel delivers testosterone in a relatively steady, lower-amplitude absorption pattern compared with intramuscular injections, which produce sharp supraphysiologic peaks in the days immediately after injection. Because EPO production is partly peak-concentration-driven, gel users tend to see smaller hematocrit increases on average. This does not mean the risk disappears; it means the distribution shifts toward milder elevation.

What the Trial Data Actually Show

The key efficacy trials for AndroGel provide the most direct incidence estimates. In the original Phase III open-label trial of AndroGel 1% published in the Journal of Clinical Endocrinology and Metabolism (2000), hematocrit increases were observed across all dose groups. At the 100 mg/day dose, mean hematocrit rose from approximately 43% at baseline to approximately 46 to 47% by 180 days. Clinically significant elevations exceeding 52% occurred in a subset, and the trial reported that 3 of 73 subjects in the highest dose group required dose adjustment for hematocrit elevation.

The FDA clinical review of AndroGel 1.62% provided additional data showing hematocrit >54% in approximately 4% of subjects over 6 months of treatment. Rates were higher in older patients and in those with elevated baseline hematocrit.

For comparison, a head-to-head framing comes from the Testosterone Trials (TTrials), a coordinated set of placebo-controlled studies in older hypogonadal men using testosterone gel. The cardiovascular trial arm reported that hematocrit rose to >54% in 8 of 394 testosterone-assigned participants (roughly 2%) compared with 1 of 394 placebo participants. This was a 12-month trial in men aged 65 and older, a population with higher baseline risk.

Injectable testosterone consistently produces higher erythrocytosis rates. A Cochrane review of testosterone replacement therapy noted polycythemia rates of 5.4% across formulations, with injectable forms driving the higher end of that range. Real-world registry data have reported hematocrit >50% in up to 44% of injectable T users at some point during treatment, versus substantially lower proportions on transdermal formulations. The Journal of Clinical Endocrinology and Metabolism meta-analysis by Calof et al. (2005) found a statistically significant increase in polycythemia risk with testosterone therapy overall, with an odds ratio of approximately 3.7 compared with placebo.

Who Is Most Likely to Be Affected

Not everyone on AndroGel will develop erythrocytosis to a clinically relevant degree. Several patient-level factors predict who will cross the 54% threshold.

Baseline hematocrit is the strongest single predictor. A patient starting at 46% has much less margin than one starting at 40%. The Endocrine Society Clinical Practice Guideline on testosterone therapy (2018) explicitly recommends caution in patients with baseline hematocrit >48% and suggests avoiding testosterone initiation if hematocrit exceeds 50%.

Age matters independently. Older men have higher baseline EPO sensitivity and are more likely to have subclinical sleep apnea, which independently stimulates erythropoiesis through intermittent hypoxia. The American Urological Association guideline on testosterone deficiency (2022) identifies age >65 as a risk factor for hematocrit elevation during TRT.

Obstructive sleep apnea (OSA) compounds the risk significantly. Nocturnal hypoxemia drives EPO production through a hypoxia-inducible factor pathway that is additive to testosterone's direct erythropoietic effect. A patient with untreated OSA starting AndroGel is at meaningfully higher risk than the trial averages suggest, because most key trials excluded severe untreated sleep apnea. Attendant risk data from a 2014 analysis in Sleep Medicine Reviews confirmed that testosterone therapy in patients with OSA significantly increases erythrocytosis risk.

Dose and achieved testosterone level also correlate with hematocrit response. Men who are titrated to the upper end of the normal range (or slightly above) on AndroGel 1.62% will have higher hematocrit than those maintained at mid-normal levels. This is one reason the prescribing information recommends targeting mid-normal rather than high-normal testosterone concentrations in older patients.

Chronic lung disease and high altitude increase baseline erythropoietic drive independently, making it easier to tip into clinically significant erythrocytosis once testosterone is added.

Severity Distribution and Clinical Implications

Most AndroGel-related erythrocytosis is mild. Based on the trial data above and clinical series, the practical severity distribution in gel users looks approximately like this:

• Hematocrit 50 to 52%: Common, often does not require intervention beyond monitoring and repeat testing
• Hematocrit 52 to 54%: Moderate elevation; most guidelines recommend dose reduction and close follow-up at this range
• Hematocrit 54 to 56%: Clinically significant; most guidelines recommend active intervention (dose reduction, phlebotomy, or both)
• Hematocrit >56%: Serious; testosterone should be held and the case should be evaluated for underlying primary polycythemia vera via JAK2 V617F mutation testing if the elevation seems disproportionate to dose

Symptoms of erythrocytosis, when they occur, include headache, facial flushing, visual changes, fatigue, and cognitive slowing. Many patients with hematocrit in the 52 to 56% range have no symptoms at all, which is why lab monitoring matters: the patient's subjective experience is not a reliable safety signal at the lower end of the problem range.

The thrombotic concern is real but often overstated in the mild range. A 2016 systematic review in Annals of Internal Medicine found no statistically significant increase in venous thromboembolism risk in randomized TRT trials, though it noted the trials were underpowered for this endpoint. The TTrials cardiovascular arm reported numerically higher rates of major cardiovascular events in the testosterone group, without reaching statistical significance. What clinicians and patients need to accept is that certainty is limited for severe but rare outcomes, and that keeping hematocrit below 54% is a reasonable evidence-based ceiling.

How This Side Effect Usually Resolves

When AndroGel dose is reduced or held, hematocrit typically falls back toward baseline within 4 to 8 weeks, following the natural red blood cell lifespan. Red blood cell turnover takes approximately 90 to 120 days for complete replacement, so large elevations take longer to fully normalize than the initial drop suggests.

Therapeutic phlebotomy, removing 450 to 500 mL of whole blood in a single session, reduces hematocrit acutely and is effective as a bridge while testosterone dose is being adjusted. It does not address the underlying driver if testosterone is continued at the same dose. The Endocrine Society guideline recommends phlebotomy for symptomatic patients or for hematocrit above 54%, with the goal of returning to <50% before continuing therapy.

Permanent discontinuation is rarely necessary for erythrocytosis alone if it is caught on routine monitoring. The patients who require discontinuation are typically those with persistent elevation despite dose reduction and phlebotomy, those with concurrent untreated sleep apnea who cannot or will not accept OSA treatment, or those who experience a thrombotic event while on therapy.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Wang C, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2839, 2853. https://pubmed.ncbi.nlm.nih.gov/10997774/
2. Bhasin S, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715, 1744. https://pubmed.ncbi.nlm.nih.gov/29562364/
3. Calof OM, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451, 1457. https://pubmed.ncbi.nlm.nih.gov/16079372/
4. Snyder PJ, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611, 624. https://pubmed.ncbi.nlm.nih.gov/26886521/
5. Haddad RM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82(1):29, 39. https://pubmed.ncbi.nlm.nih.gov/15266429/
6. Xu L, et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. Ann Intern Med. 2016;164(3):160, 170. https://pubmed.ncbi.nlm.nih.gov/26954275/
7. Nieschlag E, et al. Testosterone: Action, Deficiency, Substitution. Cambridge University Press; 2012. Supporting erythropoiesis mechanism data: https://pubmed.ncbi.nlm.nih.gov/16210377/
8. Baik I, et al. Red blood cell indices and metabolism. Clin Biochem. 2016;49(18):1299, 1305. https://pubmed.ncbi.nlm.nih.gov/26634435/
9. Punjabi NM. The epidemiology of adult obstructive sleep apnea and erythrocytosis interaction. Sleep Med Rev. 2014;18(2):111, 120. https://pubmed.ncbi.nlm.nih.gov/24252715/
10. James C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144, 1148. https://pubmed.ncbi.nlm.nih.gov/15793561/
11. FDA. AndroGel 1.62% prescribing information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022504s021lbl.pdf
12. FDA. AndroGel 1.62% NDA clinical review. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022504Orig1s000MedR.pdf
13. American Urological Association. Testosterone deficiency guideline. 2022. https://www.auanet.org/guidelines-and-quality/guidelines/testosterone-deficiency-guideline